CDC invests in Adjuvant Capital’s $300m venture fund
The UK's CDC Group has invested in a $300 million fund from Adjuvant Capital focused on accelerating the development of medical innovations for historically overlooked public health challenges.
Launched in 2019, US-based Adjuvant’s debut fund will support promising new technologies for indications that the venture capital industry has largely ignored. Adjuvant has already backed 14 companies developing technologies for high-impact indications ranging from rare conditions, such as melioidosis, to widespread global emergencies, such as COVID-19.
Each Adjuvant investment includes binding commitments to make any successfully commercialized products broadly accessible to underserved populations in low- and middle-income countries.
To finance these aims, Adjuvant has assembled a coalition of conventional and catalytic investors. The investors include traditional asset managers, multinational biopharmaceutical companies, development finance institutions, and some of the world’s largest foundations.
